Status:
RECRUITING
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Lead Sponsor:
OrsoBio, Inc
Conditions:
Hypertriglyceridemia
Nonalcoholic Fatty Liver Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoh...
Detailed Description
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoh...
Eligibility Criteria
Inclusion
- BMI ≥ 28 kg/m2 at Screening
- Fasting TG ≥ 350 mg/dL
- Subjects without diabetes or subjects with diabetes and HbA1c \< 9.5% at Screening
- Screening laboratory evaluations (eGFR, ALT, AST, INR, total bilirubin, platelet count) must fall within the protocol-defined ranges
- A clinical diagnosis of NAFLD/NASH within 5 years of Screening based on historical hepatic imaging (e.g., ultrasound, MRI, computed tomography \[CT\], or Controlled Attenuation Parameter \[CAP\] by vibration-controlled transient elastography ≥ 250 dB/m), and no documented weight loss \> 5% between the date of the historical hepatic imaging and Screening OR a historical liver biopsy within 5 years of Screening consistent with NAFLD/NASH without cirrhosis and no documented weight loss \> 5% between the date of the historical liver biopsy and Screening
- Normotensive subjects or subjects without uncontrolled hypertension, defined as systolic blood pressure \> 155 mmHg and/or diastolic blood pressure \> 90 mmHg at Screening
- A 12-lead electrocardiogram (ECG) at Screening that is normal or with abnormalities that are considered not clinically significant by the investigator
- Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 prior to first dose of study drug
- Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Exclusion
- HbA1c ≥ 9.5% at Screening
- Weight loss \> 5% during the 90 days prior to Screening
- Pregnant or lactating subjects.
- Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
- Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety
- A positive test result for human immunodeficiency virus (HIV-1) antibody, hepatitis B (HBV) surface antigen, or hepatitis C (HCV) antibody
- Medical history of liver disease other than NAFLD/NASH, including but not limited to, alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency.
- Any history of cirrhosis or decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding, or Child-Pugh-Turcotte score \> 6 at Screening
- Unstable cardiovascular disease
- History of intestinal resection or malabsorptive condition that may limit the absorption of study drug. Appendectomy and cholecystectomy are not exclusionary.
- Presence of severe peptic ulcer, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions at Screening, in the opinion of the investigator
- Any scheduled surgery during the trial period, excluding minor surgical procedures performed under local anesthesia, in the opinion of the investigator
- History of malignancy within 5 years prior to Screening except adequately treated carcinoma in situ of the cervix, and/or squamous cell cancer, or other localized non-melanoma skin cancer
- History of significant drug allergy, such as anaphylaxis or significant drug sensitivity, in the opinion of the investigator
- Known hypersensitivity to study drug, its metabolites, or formulation excipients
- Presence of any medical condition that could, in the opinion of the investigator, compromise the subject's ability to participate in the study, including a history of substance abuse or a psychiatric disorder, including any subject with a psychiatric hospital admission or emergency room visit in the 2 years prior to Screening
- Any laboratory abnormality that in the opinion of the investigator could adversely affect the safety of the subject or impair assessment of study results
- Medications or therapies prescribed or taken over-the-counter for weight loss, in the 90 days prior to Screening
- Receipt of vaccination for COVID-19 or any other live vaccine within 14 days of planned dosing of study drug
- Note: Other protocol defined Inclusion/Exclusion criteria may apply
Key Trial Info
Start Date :
August 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06564584
Start Date
August 12 2024
End Date
September 1 2025
Last Update
April 3 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
OrsoBio Research Site
Guadalajara, Jalisco, Mexico, 45116
2
OrsoBio Research Site
Zapopan, Jalisco, Mexico, 45170
3
OrsoBio Research Site
Mexico City, Mexico City, Mexico, 06700
4
OrsoBio Research Site
Mexico City, Mexico City, Mexico, 14080